TLR8 Mouse Model to Evaluate anti-HBV Agents
Toll-like receptor 8 (TLR8) plays an essential role in human antiviral immunity by recognizing ssRNA of viruses. Upon activation by specific ligands, TLR8 can trigger potent antiviral responses. Development of an in vivo preclinical model has the potential to greatly accelerate research focused on new anti-HBV agents. However, rodent TLR8 is unresponsive to human TLR8 ligands unless polyT-oligodeoxynucleotides are present.
To overcome this hurdle, WuXi Biology has established a human TLR8 transgenic mouse model of AAV/HBV infection. At the 2024 International HBV Meeting in Chicago, our scientists presented a poster showing that treatment of a TLR8 agonist in this model resulted in significant reductions of plasma HBV DNA, hepatitis B surface antigen (HBsAg) and hepatitis B e-antigen (HBeAg) levels, demonstrating the suitability of this model for evaluating TLR8 modulators.
Poster_HBV meeting 2024_TLR8 AAV HBV mouse model
Related Content
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western populations. Targeted therapies, including the use...
VIEW RESOURCEViruses have well-established causal roles in numerous human cancers. Approximately 10% of cancers globally are attributed to viral infections, primarily...
VIEW RESOURCE